Nancy Pei
Canada Guide 2025
Band 5 : Intellectual Property: Litigation
Email address
[email protected]Contact number
416.595.2761Share profile
Band 5
About
Provided by Nancy Pei
Practice Areas
Nancy Pei is a Principal in Smart & Biggar's Toronto office. With hands-on experience as a pharmacist and over 25 years of patent litigation expertise, Nancy has established a successful IP practice focused exclusively in the field of life sciences—including pharmaceuticals and biologics. As a patent litigator, Nancy advocates on behalf of innovative life sciences companies in cases relating to the PM(NOC) Regulations, in patent infringement/impeachment actions, s. 8 cases, related quantification reference proceedings and judicial review applications. She also provides advice on matters relating to patent listing, data protection, Certificates of Supplementary Protection, the Patented Medicine Prices Review Board and access to information requests. Nancy is named as a leading IP / Life Sciences legal practitioner in Chambers Canada, The Best Lawyers in Canada, LMG Life Sciences, Who’s Who Legal, MIP IP Stars: Patents, IAM Patent 1000, Benchmark Canada, The Legal 500, WIPR Leaders, Expert Guides: Women in Business Law, Patents and Life Sciences, Lexpert / ALM 500, and Lexpert's Special Edition on Litigation, and Lexpert's Special Edition on Technology and Health Sciences. Most recently, Nancy was named “Toronto Lawyer of the Year for Biotechnology" by Best Lawyers and "One of the Top 100 Women in Litigation" by Benchmark Canada.
Articles, highlights and press releases
1 item provided by Smart & Biggar
2023 Mid-Year Highlights in Canadian Life Sciences IP and Regulatory Law
In the first half of 2023, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories from January to June and summarized them for you.
2023 Mid-Year Highlights in Canadian Life Sciences IP and Regulatory Law
In the first half of 2023, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories from January to June and summarized them for you.